SCHEMBL1365518

SCHEMBL1365518

CC[C@H](Nc1oc(=O)c2ccccc2c1C(=O)CN1CCCC1=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.42
LMNA P02545 1/20 0.41
TDP1 Q9NUW8 2/20 0.38
TSHR P16473 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 2/20 0.36
CXCR2 P25025 1/20 0.35
PER2 O15055 1/20 0.35
WDR91 A4D1P6 1/20 0.35
ALDH1A1 P00352 3/20 0.35
MAPK1 P28482 2/20 0.35
POLB P06746 1/20 0.35
GRK2 P25098 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TACR2 P21452 1/20 0.35
TACR3 P29371 1/20 0.35
MEN1 O00255 1/20 0.35
RCE1 Q9Y256 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1364233 0.89 LMNA (0.39) HTTLMNATDP1TSHRSMN1; SMN2
SCHEMBL2365021 0.89 LMNA (0.39) HTTLMNATDP1TSHRSMN1; SMN2
SCHEMBL14327508 0.78 RPS6KB1 (0.40) LMNATDP1TSHRSMN1; SMN2KMT2A
SCHEMBL1365655 0.74 HTT (0.37) HTTLMNATDP1TSHRSMN1; SMN2
SCHEMBL1365654 0.74 HTT (0.37) HTTLMNATDP1TSHRSMN1; SMN2
SCHEMBL2171285 0.69 TACR3 (0.45) TSHRSMN1; SMN2KMT2AALDH1A1MAPK1
SCHEMBL1367097 0.69 TACR3 (0.35) SMN1; SMN2ALDH1A1POLBTACR3
SCHEMBL1367096 0.69 TACR3 (0.35) SMN1; SMN2ALDH1A1POLBTACR3
SCHEMBL1717924 0.69 TACR3 (0.45) LMNATDP1TSHRKDM4EALDH1A1
SCHEMBL2154227 0.68 TACR3 (0.44) TSHRSMN1; SMN2KMT2AALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415373-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2013-04-09 US disclosed
US-8415373-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2013-04-09 US disclosed
US-8415373-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2013-04-09 US disclosed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20110288120-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-11-24 US disclosed
US-20110288120-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-11-24 US disclosed
US-20110288120-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-11-24 US disclosed
EP-2350015-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2011-08-03 EP disclosed
EP-2342182-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2011-07-13 EP disclosed
WO-2010045948-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-04-29 WO disclosed
WO-2010045948-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-04-29 WO disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO disclosed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 HTT 636/4885LMNA 3107/4885TDP1 2863/4885
US-20110288120-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNK3, KCNQ3, KCNN3 HTT 4494/4885LMNA 3670/4885TDP1 4546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.